J.P. Morgan Maintains Overweight on Gen-Probe (GPRO)

J.P. Morgan is out with its report on Gen-Probe GPRO, maintaining Overweight. In a note to clients, J.P. Morgan writes, "Data from Gen-Probe's CLEAR pivotal clinical trial for the company's APTIMA HPV test were presented in a symposium on Sunday evening at the EUROGIN meeting. Results showed statistically equivalent sensitivity and statistically superior specificity, in line with prior management commentary and our and Street expectations. In light of the recent press reports that the company may be exploring strategic alternatives, however, we do not expect these in-line data to have a significant impact on the stock." Shares of GPRO closed Friday at $81.84, up 0.18% from Thursday's close.